Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Karuna Therapeutics, Inc.

At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. 
 
Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions.
 
Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don’t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
 
We invite you to join us on LinkedIn and Twitter (@KarunaTx) to stay up to date on our work.

Eventide

Fidelity

Fidelity Management and Research Company

Alexandria Venture Investments

Sands Capital Ventures

Sofinnova Investments

ARCH Venture Partners

Partner Fund Management

Pivotal bioVenture Partners

PureTech Health

Wellcome Trust

Karuna Therapeutics

Today on #February11, we join others around the globe to celebrate International Day of Women and Girls in Science. We especially want to recognize the brilliant women in science on our team. Their leadership and dedication are helping us push the boundaries of innovation in neuroscience, and the best is yet to come! #EquityinScience

Bebe Moore Campbell was a fearless mental health advocate and literary trailblazer who used her words and platform to address the impacts of racism, mental health, culture, and community. This #BlackHistoryMonth, we honor and remember her legacy as well as other Black pioneers who helped shape the #MentalHealth landscape. Learn more about their contributions: https://lnkd.in/dPDdCfR

Schizophrenia is a brain disorder that distorts the way a person thinks, feels, and behaves. While current antipsychotic therapies can help treat some symptoms, such as hallucinations and delusions, they may not fully address symptoms such as memory impairment, decision-making, and the ability to enjoy life – leading to low treatment adherence. Learn more about our commitment to addressing these needs: https://lnkd.in/gmN8ykmx 

Signs and symptoms of #schizophrenia are not “one size fits all.” Schizophrenia symptoms can differ from person to person, but they generally fall into three categories. Learn more about them here: https://lnkd.in/gmN8ykmx 

Wishing you #HappyHolidays from all of us at Karuna! May you find peace and enjoy the company of your loved ones during this season. 

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	798K -	269K 66.29%	547K 103.35%	865K 58.14%	1.94M 124.16%	2.38M 22.69%	6.78M 185.12%
accumulated other comprehensive income loss	-1K -	-7K 600%	5K 171.43%	39K 680%	-497K 1,374.36%	-3.29M 561.97%	211K 106.41%
cash and cash equivalents	1.94M -	85.53M 4,304.02%	208.93M 144.29%	53.05M 74.61%	206.95M 290.12%	248.33M 19.99%	185.82M 25.17%
cash and short term investments	1.94M -	90.51M 4,560.61%	389.40M 330.23%	322.33M 17.22%	493.99M 53.26%	1.12B 127.54%	1.26B 12.35%
common stock		1K -	3K 200%	3K 0%	3K 0%	3K 0%	4K 33.33%
deferred revenue	433K -						41.61M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory					20.89M -	28.32M 35.62%	32.83M 15.91%
long term debt	3.98M -	102K 97.44%	150K 47.06%	1.84M 1,127.33%	5.33M 189.41%	3.05M 42.83%	13.85M 354.53%
long term investments
net debt	9.72M -	-85.42M 979.12%	-208.72M 144.34%	-50.36M 75.87%	-199.45M 296.02%	-243.00M 21.84%	-169.13M 30.40%
net receivables					1.75M -	57K 96.74%	4.90M 8,496.49%
other assets
other current assets	8K -	23K 187.50%	485K 2,008.70%	1.09M 124.33%	708K 34.93%	2.34M 230.93%	14.77M 530.35%
other current liabilities	2.61M -	538K 79.36%	2.35M 337.36%	5.14M 118.61%	16.10M 212.97%	29.29M 81.91%	16.89M 42.31%
other liabilities
other non current assets		123K -	123K 0%	157K 27.64%	792K 404.46%	690K 12.88%	382K 44.64%
other non current liabilities	1K -				104K -	104K 0%
othertotal stockholders equity	676K -	123.68M 18,195.56%	72.40M 41.46%	482.95M 567.10%	790.39M 63.66%	1.69B 114.29%	2.25B 32.96%
preferred stock			393.02M -
property plant equipment net	12K -	138K 1,050%	195K 41.30%	2.87M 1,371.28%	9.54M 232.69%	7.88M 17.50%	20.51M 160.50%
retained earnings	-14.04M -	-32.10M 128.60%	-75.51M 135.23%	-144.07M 90.79%	-287.87M 99.82%	-564.21M 95.99%	-997.89M 76.87%
short term debt	7.67M -		58K -	844K 1,355.17%	2.17M 157.70%	2.28M 4.92%	2.84M 24.58%
short term investments		4.98M -	180.47M 3,521.67%	269.28M 49.21%	287.04M 6.59%	875.72M 205.09%	1.08B 22.98%
tax assets
tax payables
total assets	2.13M -	92.48M 4,243.78%	393.02M 324.99%	347.63M 11.55%	527.67M 51.79%	1.16B 120.47%	1.34B 14.86%
total current assets	2.12M -	92.22M 4,256.07%	392.71M 325.85%	344.60M 12.25%	517.33M 50.13%	1.15B 123.22%	1.32B 13.90%
total current liabilities	11.51M -	807K 92.99%	2.96M 266.54%	6.85M 131.68%	20.21M 194.95%	33.95M 67.94%	68.13M 100.70%
total debt	11.66M -	102K 99.13%	208K 103.92%	2.69M 1,190.87%	7.50M 179.44%	5.33M 28.99%	16.69M 213.21%
total investments		4.98M -	180.47M 3,521.67%	269.28M 49.21%	287.04M 6.59%	875.72M 205.09%	1.08B 22.98%
total liabilities	15.50M -	909K 94.13%	3.11M 241.91%	8.69M 179.73%	25.64M 194.97%	37.10M 44.65%	81.97M 120.98%
total liabilities and stockholders equity	2.13M -	92.48M 4,243.78%	393.02M 324.99%	347.63M 11.55%	527.67M 51.79%	1.16B 120.47%	1.34B 14.86%
total non current assets	12K -	261K 2,075%	318K 21.84%	3.03M 851.57%	10.34M 241.61%	8.56M 17.14%	20.90M 143.97%
total non current liabilities	3.99M -	102K 97.44%	150K 47.06%	1.84M 1,127.33%	5.43M 195.06%	3.15M 42.01%	13.85M 339.52%
total stockholders equity	-13.37M -	91.57M 784.99%	389.92M 325.81%	338.93M 13.08%	502.03M 48.12%	1.13B 124.34%	1.25B 11.37%

COM:KARUNATX

Karuna Therapeutics, Inc.

Last Close

329.74

15/03 20:00

Market Cap

12.60B

Beta: -

Volume Today

1.28M

Avg: -

Preview